Orexigen Therapeutics

Orexigen Therapeutics is a biopharmaceutical company focuses on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults who also have weight-related medical problems, lose weight and keep the weight off.

Revenue(FY, 2016)

$33.7 M

Market capitalization(2018-04-03)

$3.4 M

Type

Public

San Diego, US

Founded

2002

Size (employees)

132 (est)

Website

orexigen.com

Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US

Report incorrect company information

Orexigen Therapeutics Office Locations

Orexigen Therapeutics has an office in San Diego

San Diego, US (HQ)

200 3344 N Torrey Pines Ct

Show all (1)

Report incorrect company information

Orexigen Therapeutics Financials and Metrics

Orexigen Therapeutics Financials

Orexigen Therapeutics's revenue was reported to be $33.71 m in FY, 2016 which is a 37.8% increase from the previous period.

Summary

USD
Revenue (Q3, 2017)	18.9 m
Gross profit (Q3, 2017)	14.9 m
Gross profit margin (Q3, 2017), %	78.6%
Net income (Q3, 2017)	(120.4 m)
EBIT (Q3, 2017)	(22.8 m)
Market capitalization (3-Apr-2018)	3.4 m
Cash (30-Sep-2017)	45.6 m

Orexigen Therapeutics's current market capitalization is $3.4 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	3.4 m	55.5 m	24.5 m	33.7 m
Revenue growth, %		1520%	(56%)	38%
Cost of goods sold				8 m
Gross profit				25.7 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue	857 k	857 k	857 k	30.9 m	4.4 m	5.2 m	10 m	5 m	7.8 m	7 m	19.1 m	23.4 m	18.9 m
Cost of goods sold									1.8 m	1.9 m	6.2 m	6.8 m	4 m
Gross profit									6 m	5.1 m	13 m	16.5 m	14.9 m
Gross profit Margin, %									77%	72%	68%	71%	79%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	98.1 m	104.2 m	155.4 m	92.5 m
Accounts Receivable		2.6 m	6.8 m	1.1 m
Inventories	1.3 m	1.5 m	2.3 m	23.2 m
Current Assets	178.3 m	211.3 m	233.9 m	224.5 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	48.7 m	37.6 m	31.1 m	68.4 m	75.1 m	71.6 m	154.3 m	68 m	78.2 m	74.4 m	76.7 m	36.7 m	45.6 m
Accounts Receivable				32 m	4.5 m	6.8 m	4.6 m	2.8 m	2.9 m	2.1 m	6.3 m	7.6 m	19.1 m
Inventories				754 k	1.4 m	4.9 m	11.1 m	15 m	11.5 m	24 m	20.7 m	15.8 m	16.1 m
Current Assets	84.6 m	156.4 m	139.1 m	153.2 m	196.4 m	189.3 m	251.8 m	262.4 m	282.7 m	273.2 m	158.5 m	114.3 m	112.3 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(77.7 m)	(37.5 m)	(68.7 m)	(24.5 m)
Depreciation and Amortization	94 k	139 k	223 k	3.7 m
Inventories	205 k	(175 k)	(781 k)	1.5 m
Accounts Payable	(2.3 m)	2.1 m	1 m	11.8 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(56.2 m)	(24.9 m)	(49.4 m)	(38.1 m)	(17.2 m)	(39.7 m)	(50.9 m)	(22.3 m)	(47.6 m)	85 k	(69.1 m)
Depreciation and Amortization	84 k	8 k	46 k	87 k	51 k	103 k	157 k	78 k	194 k	1.7 m
Inventories				(754 k)	(158 k)	(3.7 m)	(9.8 m)	(4.1 m)	(596 k)	618 k	20.7 m
Accounts Payable	(4.2 m)	(1.2 m)	1.7 m	(1.1 m)	(3.8 m)	6.9 m	4 m	(1.9 m)	2.5 m	13.1 m	15.6 m